https://ift.tt/2IiENMH
Αρχειοθήκη ιστολογίου
-
▼
2023
(138)
-
▼
Φεβρουαρίου
(74)
-
▼
Φεβ 19
(9)
- Multifunctional Two-Dimensional Bi2Se3 Nanodiscs f...
- Downregulation of miR‐193a/b‐3p during HPV‐induced...
- The ability of magnetic resonance imaging to predi...
- Frequent EGFR exon 20 insertion in the so‐called p...
- Central odontogenic fibroma with amyloid: a diagno...
- Tixagevimab/Cilgavimab Treatment and Cardiovascula...
- The Ixodes ricinus salivary gland proteome during ...
- Characterization of protein-based risk signature t...
- Acute Posterior Multifocal Placoid Pigment Epithel...
-
▼
Φεβ 19
(9)
- ► Ιανουαρίου (64)
-
▼
Φεβρουαρίου
(74)
-
►
2022
(849)
- ► Δεκεμβρίου (61)
- ► Σεπτεμβρίου (74)
- ► Φεβρουαρίου (65)
-
►
2021
(2936)
- ► Δεκεμβρίου (59)
- ► Σεπτεμβρίου (180)
- ► Φεβρουαρίου (325)
-
►
2020
(1624)
- ► Δεκεμβρίου (293)
- ► Σεπτεμβρίου (234)
- ► Φεβρουαρίου (28)
-
►
2019
(13362)
- ► Δεκεμβρίου (19)
- ► Σεπτεμβρίου (54)
- ► Φεβρουαρίου (5586)
- ► Ιανουαρίου (5696)
-
►
2018
(66471)
- ► Δεκεμβρίου (5242)
- ► Σεπτεμβρίου (5478)
- ► Φεβρουαρίου (4835)
- ► Ιανουαρίου (5592)
-
►
2017
(44259)
- ► Δεκεμβρίου (5110)
- ► Σεπτεμβρίου (5105)
-
►
2016
(7467)
- ► Δεκεμβρίου (514)
- ► Σεπτεμβρίου (1038)
- ► Φεβρουαρίου (793)
Αναζήτηση αυτού του ιστολογίου
Κυριακή 13 Μαΐου 2018
SET8 is involved in the regulation of hyperglycemic memory in human umbilical endothelial cells
https://ift.tt/2IiENMH
AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status
AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status
AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status, Published online: 14 May 2018; doi:10.1038/s41416-018-0086-x
AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic statushttps://ift.tt/2wDeO0X
Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer
Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer
Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer, Published online: 14 May 2018; doi:10.1038/s41416-018-0083-0
Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancerhttps://ift.tt/2Kg8OgL
Tumour mutation status and melanoma recurrence following a negative sentinel lymph node biopsy
Tumour mutation status and melanoma recurrence following a negative sentinel lymph node biopsy
Tumour mutation status and melanoma recurrence following a negative sentinel lymph node biopsy, Published online: 14 May 2018; doi:10.1038/s41416-018-0088-8
Tumour mutation status and melanoma recurrence following a negative sentinel lymph node biopsyhttps://ift.tt/2IF7Ayv
Health-related quality of life after treatment for bladder cancer in England
Health-related quality of life after treatment for bladder cancer in England
Health-related quality of life after treatment for bladder cancer in England, Published online: 14 May 2018; doi:10.1038/s41416-018-0084-z
Health-related quality of life after treatment for bladder cancer in Englandhttps://ift.tt/2wBGqUe
Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study
Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study
Heterogeneous <i>MYCN</i> amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study, Published online: 14 May 2018; doi:10.1038/s41416-018-0098-6
Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Studyhttps://ift.tt/2wCbe7w
Endothelial Akt1 loss promotes prostate cancer metastasis via β-catenin-regulated tight-junction protein turnover
Endothelial Akt1 loss promotes prostate cancer metastasis via β-catenin-regulated tight-junction protein turnover
Endothelial Akt1 loss promotes prostate cancer metastasis via β-catenin-regulated tight-junction protein turnover, Published online: 14 May 2018; doi:10.1038/s41416-018-0110-1
Endothelial Akt1 loss promotes prostate cancer metastasis via β-catenin-regulated tight-junction protein turnoverhttps://ift.tt/2IB9TCJ
-
Doctors are exposed to high levels of stress in the course of their profession and are particularly susceptible to experiencing burnout. Bur...
-
Objectives: To examine the performance of the urinary biomarker panel tissue inhibitor of metalloproteinase-2 and insulin-like growth fact...
-
Abstract We examined how maternal care within the bedtime and nighttime contexts influences infant cortisol levels and patterning. Eig...